Rhazyaminine from Rhazya stricta Inhibits Metastasis and Induces Apoptosis by Downregulating Bcl-2 Gene in MCF7 Cell Line

Waqas Iqbal¹, Saleh Alkarim¹, Tahseen Kamal², Hani Choudhry³, Jamal Sabir¹, Roop S. Bora¹, and Kulvinder S. Saini¹

Abstract

Background: The role of alkaloids isolated from Rhazya stricta Decne (Apocynaceae family) (RS) in targeting genes involved in cancer and metastasis remains to be elucidated. Objective: Identify and characterize new compounds from RS, which inhibit gene(s) involved in the survival, invasion, self-renewal, and metastatic processes of cancer cells. Methods: Bioinformatics study was performed using HISAT2, stringtie, and ballgown pipeline to understand expressional differences between a normal epithelial cell line-MCF10A and MCF7. NMR and ATR-FTIR were performed to elucidate the structure of rhazyaminine (R.A), isolated from R stricta. Cell viability assay was performed using 0, 25, and 50 μg/mL of total extract of R stricta (TERS) and R.A, respectively, for 0, 24, and 48 hours, followed by scratch assay. In addition, total RNA was isolated for RNA-seq analysis of MCF7 cell line treated with R.A followed by qRT-PCR analysis of Bcl-2 gene. Results: Deptor, which is upregulated in MCF7 compared with MCF10A as found in our bioinformatics study was downregulated by R.A. Furthermore, R.A effectively reduced cell viability to around 50% (P < .05) and restricted cell migration in scratch assay. Thirteen genes, related to metastasis and cancer stem cells, were downregulated by R.A according to RNA-seq analysis. Additionally, qRT-PCR validated the downregulation of Bcl-2 gene in R.A-treated cells by less than 0.5 folds (P < .05). Conclusion: R.A successfully downregulated key genes involved in apoptosis, cell survival, epithelial-mesenchymal transition, cancer stem cell proliferation, and Wnt signal transduction pathway making it an excellent “lead candidate” molecule for in vivo proof-of-concept studies.

Keywords
alkaloids, apoptosis, breast cancer, cancer stem cells, metastasis, signaling pathways

Submitted June 10, 2018; revised September 3, 2018; accepted October 3, 2018

Introduction

Modern clinical genomic practices are now being applied for discovering targeted therapeutics against the “culprit key ring leader genes,” also called driver gene(s),¹ leading to dramatic enhancement of personalized medicine approach against specific cancers. However, the perceived success of targeted therapies still adds merely a few months of life for patients with late-stage cancers, particularly against aggressive metastatic tumors. The prospects of survival for patients with metastasis seem even murkier as adjuvant therapies developed to reduce metastasis have hit a plateau and new drugs are hard to come by. It seems imperative to translate the tumor biology knowledge that has been elucidated from the Cancer Genome Anatomy Project (CGAT)² and leverage this knowhow against metastasizing cells in designing improved treatment strategies.³ Proper utilization of technological advances in understanding tumor biology could help expedite the process of targeted new drug discoveries that are safe and more effective against metastatic tumors.

The bottleneck in tackling metastasis, a complex biological process that involves dissemination of tumor...
initiating cells evading immune response to distant organs, displays remarkable tumor heterogeneity among patients. Key clinical genomic signatures observed also vary depending on the type and stage of cancer, disseminating distant organ site(s) and period of dormancy seen before clinical diagnosis of metastasis. In one such study \(^4\) that included 41 different cancer types, it was found that breast cancer remains one of the most aggressive metastasizing malignancies and is usually recalcitrant to current therapies. \(^5\) Detecting metastasis correlates with the size of primary tumor, \(^6\) as large tumors tend to shed more cells into circulation, and the feat of metastasis quite often depends on the late-stage tumor’s growth kinetics. Cells having a knack for proliferation are more able to do so. \(^7\) This could be due to genetic heterogeneity that tumors acquire during the course of their development, from benign to highly aggressive over a long period of time, which makes the targeted new drug discovery a challenge against the metastatic process.

Breast cancer is highly prevalent among women worldwide, particularly in developed countries and its high probability of metastasizing to distant organs \(^8\) makes it one of the deadliest and most hard-to-treat malignancies. Metastasis in breast cancer patients remains a leading cause of death \(^9\) and accounts for 15% of cancer related mortalities. \(^10\) Because of lifestyle changes, the incidence of breast cancer is steadily increasing in the developing countries. \(^11\) Our understanding of cellular signal transduction pathways that are differentially regulated in cancer has been of tremendous help in devising therapeutic strategies to target tumors. Nevertheless, cancer-related mortalities remain high, requiring urgency in the development of additional means of controlling cancer progression.

Understanding the molecular biology of chemoprevention could help identify new and novel chemical entities that aid current therapeutic agents and might become standalone therapies as well. In this regard, traditional medicinal plants used for treating various ailments for centuries could be of immense therapeutic importance. Identification and purification of individual plant compounds as new chemical entities (NCEs) that inhibit signaling pathways of cancer progression and metastasis would certainly benefit and expedite the process of developing efficient treatments. \(^12\) Polyphenolic compound like epigallocatechin-3-gallate (EGCG), \(^13\) fisetin, delphinidin, and lupeol derived from dietary plants have shown promising results as therapeutic agents. \(^14\) However, these compounds affect numerous signaling pathways \(^15\) and the identification and characterization of key driver genes and the resultant signal transduction pathways affected by these compounds is necessary. \(^16\)

*Rhazy a stricta* Decne (Apocynaceae) (RS), an excellent source of antioxidants, is used for treating numerous diseases in Asia. \(^17\) Although many studies in the 1980s and 1990s identified and characterized alkaloids (> 100), flavonoids, triterpenes, and volatile substances from this plant. These studies did not link the therapeutic effect of individual compounds to specific biochemical, physiological and toxicological parameters in experimental animal models. \(^18\) Alkaloids present in herbs exhibited antiproliferative and anti-metastatic properties in both in vitro and in vivo studies. \(^19\) In recent decades, alkaloids such as camptothecin \(^20\) and *Vinca* alkaloids from *Catharanthus roseus* (L.) G.Don (Apocynaceae) \(^21\) were used as anticancer agents. Similarly, alkaloids from *R. stricta* exhibit antimicrobial \(^22\) and anticancer activities. \(^23\) Total alkaloidal extracts from RS downregulated the proliferation of the lung cancer cell line A549, \(^24\) partly by inducing the expression of NQO1, a chemopreventive enzyme. \(^25\) Elucidating key gene(s) involved in the signal transduction pathways in normal and cancerous cell lines and how their inhibition in breast cancer affects metastasis is one of the possible ways to design safe and effective breast cancer therapeutics. In this study, we have isolated and characterized individual compounds and total extracts from RS by nuclear magnetic resonance (NMR) structure, attenuated total reflectance–Fourier transform infrared spectroscopy (ATR-FTIR) spectra chemical studies. Then we examined one of the newly characterized active compounds, *rhazyaminine* (R.A), for its physiological, cellular, and molecular effects on the breast cancer cell line-MCF7, using the scratch assay, immunostaining, RNA-seq, and quantitative real-time polymerase chain reaction (qRT-PCR) to delineate its gene expression signatures and work out its specific mechanism of action.

**Materials and methods**

**Bioinformatics Analysis**

Detailed bioinformatics analyses were performed as discussed previously. \(^26\) Briefly, Fastq files obtained from European Nucleotide Archive (ENA) were mapped to human reference genome (UCSC hg38) using HISAT2. \(^27\) The resulting files were sorted and converted into BAM files using SAMtools, \(^28\) followed by annotation and abundance estimation using Stringtie. \(^29\) Differential gene expression analyses and visualization were performed using the Ballgown package in R-studio. \(^30\)

**Extraction and Isolation of Plant Alkaloids**

RS plants collected in September 2015 from the Bahrah region, located toward the east of Jeddah, Saudi Arabia, were identified by our departmental taxonomist (Dr. Khalid Hakeem) and submitted to our herbarium in the Department of Biology, King Abdulaziz University, Jeddah, Saudi Arabia. These plants are also available from Prof. Robert K.
Jensen, Department of Integrative Biology, University of Texas at Austin, Austin, TX, USA.

**Alcoholic Extract and Purification of RA From R. stricta**

Leaves of RS were dried in the absence of light. Powder obtained (1 kg), was crushed and extracted thrice by chloroform:ethanol (1:2) at a room temperature. The extract was further concentrated under low pressure obtaining dark brown residue (102 g). This was later dissolved in water containing 2% HCl and reextracted by chloroform removing nonbasic compounds. Ammonium hydroxide was used to neutralize aqueous layer and further extracted by chloroform. The chloroform extract was dried over anhydrous sodium sulfate, filtered, and evaporated using vacuum rotary evaporator, obtaining 20.88 g of crude alkaloidal extract (TERS). Purification of individual alkaloids was performed using aluminum oxide column (800 g, 80 × 2.5 cm) and equilibrated with chloroform. Thin layer chromatography (TLC) and preparative thin layer silica gel chromatography (PTCL) were performed to obtain the purified individual indole-alkaloid, R.A.

**UV-VIS, ATR-FTIR, and NMR analyses**

Total extract obtained was analyzed using ultraviolet-visible (UV-VIS) and FTIR spectrophotometers for proximal analysis. Sample was diluted 1:10 in dimethyl sulfoxide (DMSO) and scanned at 200 to 700 nm for UV-VIS analysis (Evolution 300, Thermo Fisher Scientific). Afterward, to decipher peaks and their corresponding functional groups, FTIR analysis was performed on the same samples using ATR technique (Thermoscientific ATR-FTIR instrument). 1H NMR: (400 MHz) and 13CNMR (100 MHz) were further used to characterize the sample for the detailed structural analysis. The sample was first dried under vacuum and the powder obtained was dissolved in deuterated DMSO and used for further analysis.

**Cell Line and Culture Conditions**

MCF7, a breast cancer cell line, was obtained from King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia. Cells were cultured and maintained in Dulbecco’s modified Eagle medium (DMEM-high), containing 10% fetal bovine serum (FBS) and 1% PS (penicillin and streptomycin) in a humidified incubator at 37°C with 5% CO₂. These cells were treated with 0, 25, and 50 μg/mL of TERS and R.A, respectively, for 0, 24, and 48 hours. Afterward, 100 μL of fresh media were added to each well. The methyl-thiazole tetrazolium (MTT) assay was performed, as per the instructions provided by the manufacturer. In brief, cells were incubated with 10 μL of MTT solution for 4 hours. Later, 50 μL of DMSO were added to 25 μL of media in each well, followed by homogenization thoroughly and by pipetting vigorously. Subsequently, plates were incubated at 37°C for 10 minutes. The sample in each well was mixed again and absorbance was checked at 540 nm with microplate reader (SYNERGY HTX multimode reader, BioTek).

**Immunofluorescence Staining to Observe Apoptosis**

Cells were cultured in 6-well plates and treated with 0 and 50 μg/mL of TERS and R.A, respectively, for 24 hours. The latter cells were washed with cold PBS (1×), 3 times and incubated with 0.1% Triton X 100 for 3 to 5 minutes at room temperature. Cells were washed 3 times with PBS followed by staining with Hoechst 33258 stain for 15 to 30 minutes at 37°C. Stain was removed and cells were washed with PBS 3 times and observed under inverted immunofluorescence microscope using DAPI filter (EX-350-410 nm, DM460 nm BA460-480 nm).

**Scratch/Wound Healing Assay**

Cells cultured in 6-well plates at a density of 5 × 10⁵ cells/well were allowed to form a confluent monolayer for 24 hours. A scratch was made using 10-μL pipette tip in each well and washed with 1× PBS to remove cell debris. Fresh media added to each well, followed by the addition of 50 μg/mL TERS and R.A. Pictures were taken at 0, 24, and 48 hours to observe cell migration/wound closure in the presence and absence of TERS and R.A using inverted microscope.

**RNA-seq Analysis**

MCF7 cells (1.5 × 10⁵ cells) were exposed to sublethal dose of purified R.A, that is, 50 μg/mL, in triplicates, for 24 hours at 37°C. Total RNA was isolated from drug-treated cells using Ribo-Zero reagent and RNA-seq experiment was carried out using Illumina HiSeq. RNA was ribo-depleted (Ribo-Zero, Epicentre) before preparing cDNA library (ScriptSeq epicentre). Each cDNA was sequenced in multiplex generating >40 million 100 bp reads per sample. The Illumina reads were mapped to the assembled reference transcriptome sequence using the software TopHat and
Cufflinks. Differentially expressed genes were identified and functionally annotated. Clusters of differentially expressed transcripts were annotated to identify GO/KEGG pathways. Genes were considered significantly upregulated in alkaloid-treated MCF7 cells in comparison with DMSO-treated control cells if log₂ fold change > 1; P value < .05 and genes were considered significantly downregulated if log₂ fold change < −1; P value < .05 in alkaloid-treated MCF7 cells as compared with DMSO control.

**RNA Extraction and qPCR Analysis**

Cells were grown in 6-well plates at a density of 5 × 10⁵ and were treated with control and 50 μg/mL of TERS and R.A for 24 hours. mRNA was extracted using Trizol reagent (Invitrogen). The pellet was dissolved in 50 μL RNase-free water and quantified using NanoDrop. A total of 1 μg/μL of RNA was used to prepare cDNA. qPCR was performed (Bio-Rad, CFX Connect, Real-Time System) with SYBR green master mix to analyze the expression of Bcl-2 gene. The conditions used were as following. Initial activation at 98°C for 30 seconds followed by 39 cycles of 98°C for 30 seconds and 60°C for 30 seconds. The sequences of primers used are described in Supplementary Table 1 (available in the online version of the article).

**Statistical Analysis**

All the data are represented as mean ± standard error. Significance was analyzed using one-way analysis of variance test. P < .05 was considered significant.

**Results**

**Differential Expression Comparison Between MCF10A and MCF7**

To evaluate the differential expression of genes between MCF10A and MCF7 cell lines, RNA-seq data was downloaded from ENA and analyzed, as described earlier. A total of 935 genes with at least 2-fold differential expression were identified (Supplementary Table 2, available in the online version of the article). A scatterplot showing the distribution of differentially expressed genes (log₂) depicts the significant genes as blue dots (Supplementary Figure 1a, available in the online version of the article). Multidimensional scaling (MDS) shows the relationship between samples. Samples closely correlated are grouped together. MCF10A samples, colored in red, and MCF7 samples, colored in blue on the MDS plot, are seen clustering in close proximity, respectively (Supplementary Figure 1b). In addition, we observed the distribution of differentially expressed genes; the histogram between dashed lines represents genes that are 4-fold differentially expressed (Supplementary Figure 1c). A heatmap of log₂ (FC > 2) genes between the 2 datasets shows the gene expression differences between epithelial cell line (MCF10A) and MCF7 (Supplementary Figure 1d).

**Isolation and Structural Determination of Individual Alkaloid**

Total extract and individual alkaloids were isolated, and fractionated as discussed, under the Materials and Methods section. The structure of individual alkaloid-R.A was determined, and further validated by the NMR and FTIR spectroscopic studies, as shown in Figure 1.

**Effect of Crude Extract and Isolated Compound on Cell Viability**

The effectiveness of crude extract and individual alkaloid from RS was investigated at different concentrations on MCF7 cell line. Cytotoxicity of crude extract has already been reported by our departmental colleague. In this study, evaluation of cytotoxicity of R.A in comparison to TERS was performed as outlined below. After investigating the optimum dosage for MTT assay (data not shown here), two doses (25 and 50 μg) were selected for TERS and R.A, respectively. MTT assay was performed to assess the cellular cytotoxicity. The assay indirectly measures cell growth by observing the amount of tetrazolium compound converted into colored formazan whose absorbance was measured at the end of the assay. Both TERS and R.A showed cellular cytotoxicity toward MCF7 cell line in a dose and time dependent manner, as shown in Figure 2.

**Induction of Apoptosis in MCF7 Cell Line**

Apoptosis in MCF7 cell line by TERS and R.A was observed under the fluorescence microscope. Cells were treated with TERS and R.A for 24 hours, and later stained with the Hoechst 33258 dye. This stain binds to A-T rich regions in DNA and emits blue fluorescence that could be observed under a 4′,6-diamidino-2-phenylindole DAPI filter. Normal cells emit uniform fluorescence while apoptotic cells emit bright fluorescence due to the densely stained condensed genomic DNA. Induction of apoptosis was observed in MCF7 cell lines treated with TERS and R.A. Emission of bright blue fluorescence was observed in both TERS- and R.A-treated cells (Figure 3). Our data indicate the induction of apoptosis in MCF7 cells by both crude extract and individual alkaloid-R.A.

**Inhibition of Cell Migration**

Scratch assay is a technique used to measure cell migration in vitro where a scratch is made in a cell monolayer and
Images are captured at different time points during cell migration (wound healing). Images were compared to evaluate migration inhibition by TERS and R.A at 24 and 48 hours. Scratch was made in monolayer of confluent MCF7 cells. Cells were exposed to 0 and 50 μg of TERS and R.A for 24 and 48 hours. Both TERS and R.A impeded wound healing (migration) of MFC7 cell line compared with control (Figures 4 and 5).

Real-time PCR was performed to evaluate the quantitative expression of Bcl-2 gene in MCF7 cell line after treatment with TERS and R.A for 24 hours. Both TERS and R.A reduced the expression of Bcl-2 gene in MCF7 cell line (Figure 6).

**Figure 1.** Nuclear magnetic resonance (NMR) structure, attenuated total reflectance–Fourier transform infrared (ATR-FTIR) spectra of rhazynamine/dimethyl sulfoxide (R.A/DMSO) solution and blank DMSO: (a) Structure of isolated compound. (b) Structure of DMSO used to dissolve the extracted compound. (c). The FTIR spectra of the samples were obtained for the compound’s identification. ATR-FTIR spectra of R.A (red) in DMSO and blank DMSO (blue). In the FTIR spectrum of DMSO, the two small peaks located at 2910 cm$^{-1}$ were due to the C-H asymmetric stretching vibrations. Other peaks at 1300, 1200, and 1000 cm$^{-1}$ represent –CH$_3$ bending and S-O stretching vibrations. In addition to the presence of these peaks, two new peaks appeared at the 3400 and 1600 cm$^{-1}$ in the FTIR spectrum of R.A/DMSO solution. The broad peak at 3400 cm$^{-1}$ is due to the N-H asymmetric stretching and at 1629 cm$^{-1}$ is due to the C=O ester group. The aromatic C-H wagging and twisting vibrations are confirmed by the peak locks located below 1000 cm$^{-1}$. (d) Ultraviolet-visible (UV-VIS) spectral data of R.A/DMSO with different dilutions. The visual appearance of R.A/DMSO solution was a colorless and nearly transparent liquid. In all the 2 UV-VIS spectra of the samples, a single peak at 200 nm was observed which is due to the electronic transition from the n to π*. Moreover, the peak’s intensity increased with increasing the R.A amount in the R.A/DMSO obeying the Beer-Lambert’s law. No other peak in the visible region of the spectra was identified, which represents that the solution was colorless and transparent in nature.

**Figure 2.** Cytotoxicity of total extract of Rhazyia stricta (TERS) and rhazynamine (R.A). Breast cancer cells, MCF7, were treated with 0, 25, and 50 μg/mL TERS and R.A for 24 and 48 hours. Percentage of relative cell viability was evaluated compared with control (0 μg/mL). All data presented as mean ± SEM. Data were analyzed by one-way analysis of variance where * indicates significance ($P < .05$) and ** indicates high significance ($P < .001$).
Differential Expression of Metastasis-Related Genes

MCF7 cell line was treated with 50 μg/mL of R.A for 24 hours and total RNA was extracted. RNA-seq was performed and R.A-treated MCF7 samples were compared with control samples. A total of 43 genes were \( \log_2 \) differentially expressed between control and R.A-treated cells (Supplementary Table 3, available in the online version of the article). We further analyzed the role of differentially
Iqbal et al

expressed genes to elucidate their specific role in the regulation of metastasis. We searched the role of all the 43 genes against articles present in Google Scholar and PubMed library. Thirteen of the genes downregulated by R.A treatment had a direct or indirect role in metastasis (Table 1). A schematic representation of these genes and their role in metastasis is shown in Figure 7.

Discussion

Alkaloids derived from different plant sources have proven efficacy in suppressing various genes involved in the development of oncogenesis. This is because of their multifaceted role in modulating signal transduction pathways of cell proliferation, apoptosis and metastasis.\(^\text{50}\) The widely used drug paclitaxel was derived from the bark of Taxus brevifolia Nutt (Taxaceae) and is currently employed in the treatment of various malignancies, such as breast, lung, and ovarian cancer.

Our study has shown the effectiveness of TERS and R.A on cellular cytotoxicity. Both TERS and R.A proved cytotoxic (Figure 2) and were effective in inducing apoptosis as DNA condensation was observed in Hoechst-stained cells after 24 hours of treatment (Figure 3). Further investigations into the antimetastatic potential of both TERS and R.A in a scratch assay on MCF7 cells after 24 and 48 hours of treatment showed clear reduction in the wound-healing ability (Figure 4). Comparative bioinformatics analyses, between MCF10A and MCF7, helped us elucidate and establish differential gene expression patterns, which are the key determinants of cancer progression. In RNA-seq data analyses, we found numerous genes deregulated by R.A (Supplementary Table 3, available in the online version of the article), which could be of interest to us for targeted drug discovery, as the regulation of these genes could have significant influence in abetting metastasis (Table 1). Another major finding was the downregulation of Deptor (DEP domain-containing mTOR-interacting protein) having role in metastasis and chemoresistance by R.A (Table 1), which is one of the 935 genes upregulated in MCF7 cell line compared with MCF10A (Supplementary Table 2). We found 13 genes associated with metastasis or metastatic cancer stem cells (mCSCs). Epithelial-mesenchymal transition (EMT), a process during which cells in the epithelial state undergo transition to the mesenchymal (fibroblast-like) state, is crucial for cancer metastasis.\(^\text{57}\) We discovered that PIK3R3, DYPD, and CDH6, key genes involved in EMT, were downregulated by R.A. HABP2, EFNB2, COL7A1, CD24, FAM84B, and HK2 involved in migration/invasion and proliferation of CSCs were also downregulated.
Another key aspect of metastasis is the upregulation of the Wnt/β-catenin pathway, and its inhibition could block metastatic process by influencing breast CSCs. We observed that R.A treatment downregulated two genes, LGR4 and CAMK2B, which are key players in the Wnt/β-catenin pathway. Another major finding was the downregulation of the Bcl-2 gene (Figure 6), an antiapoptotic member of the Bcl-2 gene family involved in migration, invasion, and metastasis. Bcl-2 upregulation is also associated with increased survival in cancer cells. As already evident from various studies, the Bcl-2 gene has diverse roles in tumor initiation, maintenance, progression, invasion, apoptosis and  

### Table 1. List of Differentially Expressed Genes: Differential Expression of Metastasis-Related Genes in Untreated Control and R.A-Treated MCF7 Cell Line.

| No. | Gene_ID | Regulation | log2 | p Value | q Value | Function |
|-----|---------|------------|------|---------|---------|----------|
| 1   | PIK3R3  | Down       | -1.18332 | 0.00005 | 0.00979194 | EMT51 |
| 2   | DPYD    | Down       | -1.08747 | 0.00005 | 0.00979194 | EMT52 |
| 3   | HABP2   | Down       | -0.995176 | 0.00005 | 0.00979194 | Migration53 |
| 4   | LGR4    | Down       | -1.07416 | 0.00015 | 0.0239645 | Stem cell marker, β-catenin signaling46,47 |
| 5   | EFNB2   | Down       | -1.45286 | 0.00005 | 0.00979194 | Migration, proliferation, stem cell marker46,47 |
| 6   | BCL2    | Down       | -0.869782 | 0.0001 | 0.0171014 | Overexpression in CSCs48 |
| 7   | HK2     | Down       | -1.47343 | 0.00005 | 0.00979194 | Migration, CSC regulation49 |
| 8   | COL7A1  | Down       | -1.21242 | 0.00005 | 0.00979194 | Invasion50 |
| 9   | CDH6    | Down       | -0.997011 | 0.00015 | 0.0239645 | Promotes EMT51 |
| 10  | CD24    | Down       | -0.859687 | 0.0003 | 0.0433643 | CSCs’ marker52 |
| 11  | CAMK2B  | Down       | -2.26583 | 0.00005 | 0.00979194 | Wnt53 |
| 12  | FAM84B  | Down       | -1.23326 | 0.0001 | 0.0171014 | Upregulation in CSCs, metastasis54 |
| 13  | DEPTOR  | Down       | -1.25133 | 0.0001 | 0.0171014 | Enhances metastasis, chemoresistance55 |

Abbreviations: EMT, epithelial-mesenchymal transition; CSC, cancer stem cell.

**Figure 7.** A schematic representation of genes inhibited and their role in abetting metastasis: Rhazynamine (R.A) inhibited a number of genes that have been previously documented to play role in epithelial-mesenchymal transition (EMT), migration of cancer cells to secondary sites, invasiveness and proliferation of cancer stem cells (CSCs).
metastasis. Almost 75% of primary breast tumors exhibit elevated levels of Bcl-2 expression. Clearly, the development of numerous new drugs targeting the BH3 domain of Bcl-2 has been central to curbing cancer. In development of numerous new drugs targeting the BH3 expression. Clearly, the Bcl-2 exhibit elevated levels of Mcl-1, Bcl-2 or Bcl-xL however, still remains elusive. siRNA knockdown or upregulation of Mcl-1, Bcl-2 or Bcl-xL in colorectal cancer cell lines (HT29 and SW480) substantially decreased migration and invasion. The effect was increasingly profound for Bcl-2 gene. Furthermore, Bcl-2 overexpression in MCF7 ADR, human breast cancer cell line, not only enhances tumorigenicity but also reduces latency period, leading to lung metastases. This demonstrates the multifaceted role that Bcl-2 plays and its importance as a plausible small molecule drug target.

Conclusion

A comparative bioinformatics study of MCF7 and MCF10A cell lines led us to elucidate a number of key genes central to breast cancer and metastasis. This gave us an insight on gene expression signatures, which could be exploited for new drug discovery research. Having molecular signature–based knowledge in hand we isolated and characterized RA, a new chemical entity from R. stricta. R.A downregulated Bcl-2 gene and modulated several genes crucial to metastasis and cancer stem cells. Further studies in NCI-60 panel of human tumor cell lines for establishing the anticancer and antimetastatic potential of R.A are warranted.

Acknowledgments

We are grateful to Dr. Ayman I. Elkady, our colleague from the Department of Biology, King Abdulaziz University, Jeddah, for his valuable assistance, guidance, and unflagging support on numerous occasions. We are indebted to the staff in High Performance Computing Center, King Abdulaziz University for allowing us access to the Aziz supercomputer. We also thank Dr. Khalid Hakeem of Plant Sciences Section, Department of Biology for inspecting plant material.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was partially funded by Deanship of Scientific Research (DSR) at King Abdulaziz University (KAU), Jeddah, Saudi Arabia represented by the Unit of Strategic Technologies Research through the Project No. (D 008/431) titled “Identification and Isolation of Salt and Heat-Tolerance Genes of R. stricta and Detection of Metabolites and Their Therapeutic Effects via Cheminformatics.”

Supplemental Material

The online supplementary material is available at http://journals.sagepub.com/doi/suppl/10.1177/1534735418809901

References

1. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546-1558.
2. Strausberg RL, Buetow KH, Emmert-Buck MR, Klausner RD. The Cancer Genome Anatomy Project: building an annotated gene index. Trends Genet. 2000;16:103-106.
3. Wan L, Pantel K, Kang Y. Tumor metastasis: moving new biological insights into the clinic. Nat Med. 2013;19:1450-1464.
4. Disibio G, French SW. Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med. 2008;132:931-939.
5. Chen H, Shah AS, Girgis RE, Grossman SA. Transmission of glioblastoma multiforme after bilateral lung transplantation. J Clin Oncol. 2008;26:3284-3285.
6. Heimann R, Hellman S. Aging, progression, and phenotype in breast cancer. J Clin Oncol. 1998;16:2686-2692.
7. Weinberg RA. The Biology of Cancer. New York, NY: Garland Science; 2014.
8. Weigelt B, Peterse JL, van’t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5:591-602.
9. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5-29.
10. Global Burden of Disease Cancer Collaboration; Fitzmaurice C, Dicker D, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1:505-527.
11. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003;3:768-780.
12. Ahmad N, Mukhtar H. Green tea polyphenols and cancer: biologic mechanisms and practical implications. Nutr Rev. 1999;57:78-83.
13. Siddiqui IA, Adhami VM, Bharali DJ, et al. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res. 2009;69:1712-1716.
14. Murtaza I, Saleem M, Adhami VM, Hafeez BB, Mukhtar H. Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells. Cancer Res. 2009;69:1156-1165.
15. Khan N, Afq F, Saleem M, Ahmad N, Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol (−)-epigallocatechin-3-gallate. Cancer Res. 2006;66:2500-2505.
16. Hafeez BB, Siddiqui IA, Asim M, et al. A dietary anthocyanidin delphinidin induces apoptosis of human prostate cancer.
PC3 cells in vitro and in vivo: involvement of nuclear factor-
kappaB signaling. Cancer Res. 2008;68:8564-8572.

17. Khan N, Afaq F, Kweon MH, Kim K, Mukhtar H. Oral consumption of pomegranate fruit extract inhibits growth and progression of primary lung tumors in mice. Cancer Res. 2007;67:3475-3482.

18. Khan N, Asim M, Afaq F, Abu Zaid M, Mukhtar H. A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res. 2008;68:8555-8563.

19. Kim I, He YY. Targeting the AMP-activated protein kinase for cancer prevention and therapy. Front Oncol. 2013;3:175.

20. Gilani SA, Kikuchi A, Shinwari ZK, Khattak ZI, Watanabe KN. Phytochemical, pharmacological and ethnobotanical studies of Rhazya stricta Decne. Phytother Res. 2007;21:301-307.

21. Marwat SK, Fazal-ur-Rehman, Usman K, Shah SS, Anwar N, Ullah I. A review of phytochemistry, bioactivities and ethno medicinal uses of Rhazya stricta Decne (Apocynaceae). Afr J Microbiol Res. 2012;6:1629-1641.

22. Iqbal S, Banger MI, Akhtar M, Anwar F, Ahmed KR, Anwer T. Antioxidant properties of methanolic extracts from leaves of Rhazya stricta. J Med Food. 2006;9:270-275.

23. Lu JJ, Bao JI, Chen XP, Huang M, Wang YT. Alkaloids isolated from natural herbs as the anticancer agents. Evid Based Complement Alternat Med. 2012;2012:485042.

24. Huang M, Gao H, Chen Y, et al. Chinmmitcan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo. Clin Cancer Res. 2007;13:1298-1307.

25. Li W, Shao Y, Hu L, et al. BM6, a new semi-synthetic vinca alkaloid, exhibits its potent in vivo anti-tumor activities via its high binding affinity for tubulin and improved pharmacokinetic profiles. Cancer Biol Ther. 2007;6:787-794.

26. Verpoorte R. Antimicrobially active alkaloids. In: Roberts MF, ed. Alkaloids: Biochemistry, Ecology, and Medicinal Applications. Boston, MA: Springer; 1998:397-433.

27. Khan R, Baeshen MN, Saini KS, Bora RS, Al-Hejin AM, Baeshen NA. Antibacterial activities of Rhazya stricta leaf extracts against multidrug-resistant human pathogens. Biotechnol Biotechnol Equip. 2016;30:1016-1025. doi:10.1080/13012818.2016.1209087

28. Elkady AI. Crude alkaloidal extract of Rhazya stricta inhibits cell growth and sensitizes human lung cancer cells to cisplatin through induction of apoptosis. Genet Mol Biol. 2013;36:12-21.

29. El Gendy MAM, Ali BH, Michail K, Siraki AG, El-Kadi AOS. Induction of quinone oxidoreductase 1 enzyme by Rhazya stricta through Nrfl2-dependent mechanism. J Ethnopharmacol. 2012;144:416-424.

30. Iqbal W, Alkarim S, Mohammed Ali HSH, Saini KS. CEACAM gene family: a circuitous journey towards metastasis in breast cancer. MOJ Immunol. 2017;5:164.

31. Barutcu AR, Lajoie BR, McCord RP, et al. Chromatin interaction analysis reveals changes in small chromosome and telomere clustering between epithelial and breast cancer cells. Genome Biol. 2015;16:214.

32. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;12:357-360.
51. Gugnoni M, Sancisi V, Gandolfi G, et al. Cadherin-6 promotes EMT and cancer metastasis by restraining autophagy. *Oncogene*. 2017;36:667-677.
52. Horimoto Y, Arakawa A, Sasahara N, et al. Combination of cancer stem cell markers CD44 and CD24 is superior to ALDH1 as a prognostic indicator in breast cancer patients with distant metastases. *PLoS One*. 2016;11:e0165253.
53. Serviss JT, Johnsson P, Grandér D. An emerging role for long non-coding RNAs in cancer metastasis. *Front Genet*. 2014;5:234.
54. Wong N, Gu Y, Kapoor A, et al. Upregulation of FAM84B during prostate cancer progression. *Oncotarget*. 2017;8:19218-19235.
55. Parvani JG, Davuluri G, Wendt MK, et al. Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to surviving expression. *Neoplasia*. 2015;17:317-328.
56. Millimouno FM, Dong J, Yang L, Li J, Li X. Targeting apoptosis pathways in cancer and perspectives with natural compounds from mother nature. *Cancer Prev Res (Phila)*. 2014;7:1081-1107.
57. Heerboth S, Housman G, Leary M, et al. EMT and tumor metastasis. *Clin Transl Med*. 2015;4:6.
58. De P, Carlson JH, Wu H, Marcus A, Leyland-Jones B, Dey N. Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers. *Oncotarget*. 2016;7:43124-43149.
59. Jang GB, Kim JY, Cho SD, et al. Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype. *Sci Rep*. 2015;5:12465.
60. Koehler BC, Scherr AL, Lorenz S, et al. Beyond cell death—antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro. *PLoS One*. 2013;8:e76446.
61. Um HD. Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: a review focusing on mitochondrial respiration and reactive oxygen species. *Oncotarget*. 2016;7:5193-5203.
62. Piao LS, Hur W, Kim TK, et al. CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. *Cancer Lett*. 2012;315:129-137.
63. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. *Nat Rev Mol Cell Biol*. 2014;15:49-63.
64. Dawson SJ, Makretsov N, Blows FM, et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. *Br J Cancer*. 2010;103:668-675.
65. Millimouno FM, Dong J, Yang L, Li J, Li X. Targeting apoptosis pathways in cancer and perspectives with natural compounds from mother nature. *Cancer Prev Res (Phila)*. 2014;7:1081-1107.
66. Heerboth S, Housman G, Leary M, et al. EMT and tumor metastasis. *Clin Transl Med*. 2015;4:6.
67. De P, Carlson JH, Wu H, Marcus A, Leyland-Jones B, Dey N. Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers. *Oncotarget*. 2016;7:43124-43149.
68. Jang GB, Kim JY, Cho SD, et al. Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype. *Sci Rep*. 2015;5:12465.
69. Yang XK, Xu MY, Xu GS, Zhang YL, Xu ZX. In vitro and in vivo antitumor activity of scutebarbatine A on human lung carcinoma A549 cell lines. *Molecules*. 2014;19:8740-8751.
70. Liew SY, Looi CY, Paydar M, et al. Subditine, a new monoterpenoid indole alkaloid from bark of *Nauclea subdita* (Korth.) Steud. induces apoptosis in human prostate cancer cells. *PLoS One*. 2014;9:e87286.
71. Takaoka A, Adachi M, Okuda H, et al. Anti-cell death activity promotes pulmonary metastasis of melanoma cells. *Oncogene*. 1997;14:2971-2977.
72. Del Bufalo D, Biroccio A, Leonetti C, Zupi G. Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line. *FASEB J*. 1997;11:947-953.